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Abstract
Background: The role of the Fcγ receptor IIa (FcγRIIa), a receptor for C-reactive protein (CRP),
the classical acute phase protein, in atherosclerosis is not yet clear. We sought to investigate the
association of FcγRIIa genotype with risk of coronary heart disease (CHD) in two large population-
based samples.
Methods: FcγRIIa-R/H131 polymorphisms were determined in a population of 527 patients with
a history of myocardial infarction and 527 age and gender matched controls drawn from a
population-based MONICA- Augsburg survey. In the LURIC population, 2227 patients with
angiographically proven CHD, defined as having at least one stenosis ≥ 50%, were compared with
1032 individuals with stenosis <50%.
Results: In both populations genotype frequencies of the FcγRIIa gene did not show a significant
departure from the Hardy-Weinberg equilibrium. FcγRIIa R(-131) → H genotype was not
independently associated with lower risk of CHD after multivariable adjustments, neither in the
MONICA population (odds ratio (OR) 1.08; 95% confidence interval (CI) 0.81 to 1.44), nor in
LURIC (OR 0.96; 95% CI 0.81 to 1.14).
Conclusion: Our results do not confirm an independent relationship between FcγRIIa genotypes
and risk of CHD in these populations.
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Background
Fcγ receptors (FcγR) bind the Fc portion of immunoglob-
ulin (Ig) and thereby link antigen recognition by antibod-
ies with cell-based effector mechanisms [1-4]. Although
FcγRIIa (or CD32) [GenBank: BC019931] is expressed on
various cells involved in atherogenesis like monocytes,
macrophages, platelets and neutrophils, and though it has
been detected immunocytochemically in human athero-
sclerotic lesions, its potential active role in atherosclerosis
is still a matter of controversy [5,6]. Calverley et al.
showed FcγRIIa expression to be increased in platelets of
patients experiencing an acute atherothrombotic event or
who were clinically healthy but had two or more athero-
sclerosis risk factors; by contrast, Pfeiffer et al. reported
decreased expression of FcγRIIa on peripheral blood
monocytes in patients with severe atherosclerosis [7,8].
A specific genetic polymorphism affecting its function has
been described in the FcγRIIa, causing an amino acid
exchange from arginine (R) to histidine (H) at position
131. H131 is the only FcγR that recognizes IgG2 effi-
ciently. The codominantly expressed R131 allele has affin-
ity for IgG3 and IgG1 subtypes and exhibits a strongly
diminished binding to IgG2 [9].
Increasing evidence suggests that immune processes play
a substantial role in atherosclerosis [10]. It has been
hypothesized that immune complexes containing immu-
nogenic molecules such as low-density lipoproteins
(LDL), heat shock proteins, or microorganisms may acti-
vate FcγRIIa within atherosclerotic plaques, subsequently
leading to the production and secretion of mediators [11].
On the one hand results from the Rotterdam study have
suggested that the IgG subclass specificity of the H131
allele protects against advanced peripheral atherosclero-
sis. Since the protective effect was independent of tradi-
tional cardiovascular risk factors, the authors suggested
investigating whether the H131 allele also protects against
clinical cardiovascular events [12].
On the other hand, Gavasso et al. assessed the relation-
ship between polymorphisms in three different FcγR
genes and coronary artery disease (CAD). In 882 patients
undergoing coronary angiography, no association was
found between the FcγRIIa genotypes and CAD [13].
FcγRIIa has been identified as the major receptor for
human C-reactive protein (CRP) [14]. Pan et al. reported
the presence of FcγR's on human EC and their upregula-
tion by cytokines. They described the receptor expression
in native EC's being low and getting upregulated by
cytokines [15].
CRP, the classical acute phase protein, is a strong cardio-
vascular risk marker, and responds rapidly to various
proinflammatory stimuli [16-18]. Furthermore, several
recent studies also suggest a proatherogenic role for CRP.
Mechanisms, in support of such a notion include the
acceleration of the progression of atherosclerosis in apol-
ipoprotein E-deficient mice, suggesting direct involve-
ment of CRP in atherogenesis [19], and its presence in
atherosclerotic lesions but not in the normal vessel wall
[20,21].
Devaraj et al. showed that CRP binds to FcγR, mainly
FcγRIIa on human aortic endothelial cells (HAEC) to
mediate its biological activity, and incubation of HAEC
with monoclonal antibodies to FcγRIIa before addition of
CRP markedly reversed the proatherogenic effects of CRP
on prostacyclin synthase and IL-8. Similar results were
observed with intercellular adhesion molecule (ICAM)-1,
vascular cell adhesion molecule (VCAM)-1, cGMP and
PAI-1 [22]. CRP stimulated matrix metalloproteinase-1
(MMP-1) expression in U937 histiocytes through FcγRII
and extracellular signal-regulated kinase (ERK) pathway,
suggesting that CRP may be involved in plaque destabili-
zation [23].
Recently, research in this field has focused on the two
allelic variants of FcγRIIa. It has been shown that CRP
binding is allele-specific. CRP binds with high avidity to
monocytes and neutrophils from R131 homozygotes, but
shows strongly decreased binding to cells from FcγRIIa
H131 homozygotes and intermediate binding to FcγRIIa
heterozygotes, implying that the HH131 genotype may
thus be less susceptible to coronary heart disease (CHD)
[24].
Since there is no direct evidence that the polymorphism
may be associated with a lower risk of CHD in vivo we
sought to investigate the potential association between
the allelic status of FcγRIIa and risk of CHD in two large
independent populations.
Methods
Study populations
MONICA Study
The MONICA (MONItoring of trends and determinants
in CArdiovascular disease) Augsburg study was part of the
multinational World Health Organisation MONICA
project. From 1984/85 to 1994/95, three population-
based MONICA surveys had been conducted, and a
regional myocardial infarction registry had been estab-
lished. Altogether 13,427 subjects of caucasian back-
ground (6,725 men and 6,702 women) were
prospectively followed within the frame of the KORA
(Cooperative Research in the Region of Augsburg). The
design of the project has been described in detail else-
where [25]. Five hundred and twenty seven patients with
a history of myocardial infarction (MI), identified fromBMC Medical Genetics 2009, 10:46 http://www.biomedcentral.com/1471-2350/10/46
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the Augsburg Myocardial Register 1996/97, (KORA-B),
served as cases, who were compared to 527 age- and gen-
der-matched controls drawn from the population-based
MONICA Augsburg survey, conducted in 1994/95.
The presence of CHD was defined as a validated diagnosis
of non- fatal and fatal MI according to MONICA diagnos-
tic criteria [26]. Diabetes mellitus (DM) was defined by a
positive history, treatment with hypoglycemic drugs or
having either random plasma glucose ≥ 200 mg/dl or a
HbA1c ≥ 6.5%. Actual hypertension was defined as being
aware of hypertension and/or having blood pressure val-
ues ≥ 160 mm Hg systolic and/or ≥ 95 mg Hg diastolic.
Baseline information on smoking habits, alcohol con-
sumption, medical history, and body mass index (BMI)
was gathered by trained medical staff during a standard-
ized interview.
LURIC Study
A total of 3,297 patients with suspect CHD participating
in the LUdwigshafen RIsk and Cardiovascular Health
(LURIC) study were included in these analyses. The
design of the study has been described in detail elsewhere
[27]. Analyses are based on individuals from whom com-
plete data were available (n = 3,259). Exclusion criteria
were incomplete angiographic data, missing data on any
of the considered risk factors, acute infectious diseases, or
evidence of malignant diseases -possibly associated with
an acute phase reaction. All subjects were of caucasian
background.
Thus, 2,227 patients with significant CHD were compared
with 1,032 individuals with stenoses <50% (control
group). DM was diagnosed according to the criteria of the
American Diabetes Association (ADA) if plasma glucose
was >1.25 g/L in the fasting state or 2.00 g/L two hours
after an oral glucose load, which was performed in all sub-
jects not previously diagnosed as having DM, or if individ-
uals received oral hypoglycemic drugs or insulin.
Hypertension was defined as having a systolic and/or
diastolic blood pressure > 140 and/or 90 mm Hg or hav-
ing a history of hypertension.
All subjects underwent a standardized interview con-
ducted by trained personnel. The information obtained
included current health status -especially physician diag-
nosed hypertension and DM, medical history, and current
medication. Furthermore, sociodemographic characteris-
tics and lifestyle habits were recorded.
Both studies have been approved by the appropriate eth-
ics committees and have therefore been performed in
accordance with the Declaration of Helsinki.
Laboratory methods
MONICA Study
A non-fasting venous blood sample was obtained from all
study participants while sitting. Total cholesterol was
determined with an enzymatic method (CHOD-PAP,
Roche Diagnostics, Mannheim, Germany). LDLc was
measured after precipitation with dextran sulphate
(Quantolip LDL, Immuno AG, Vienna, Austria) and HDLc
after precipitation with phosphatungstate acid and Mg2+
(Roche Diagnostics, Mannheim, Germany). CRP meas-
urements were done by a high-sensitivity latex enhanced
nephelometric assay on a BN II analyser (Dade Behring,
Marburg, Germany).
LURIC Study
Venous blood was drawn from all participants early in the
morning before cardiac catheterization. Total cholesterol
was determined enzymatically. HDLc was determined
after precipitation with phosphatungstate acid and Mg2+
(Roche Diagnostics, Mannheim, Germany). CRP concen-
trations were determined using the same high-sensitivity
latex-enhanced nephelometric assay on a BN II analyser
(N Latex CRP mono, Dade Behring, Marburg, Germany).
All laboratory analyses in both studies were done in a
blinded fashion.
Analysis of the R(-131) → H polymorphism of the FcγRIIa 
gene in MONICA
Genomic DNA has been isolated from white blood cells
by standard methods [28]. FcγRIIa genotyping was per-
formed with matrix-assisted laser desorption/ionisation
time-of-flight (MALDI-TOF) mass spectrometry [29].
Analysis of the R(-131) → H polymorphism of the FcγRIIa 
gene in LURIC
Genomic DNA was prepared from EDTA anticoagulated
blood. Receptor polymorphism was determined from
polymerase chain reaction and restriction typing. The
primers for amplification were 5'-CCTTGGACAGTGAT-
GGTCAC-3' and 5'-TGGAAAATCCCAGAAATTCTCGC-3'.
Amplification products were digested with BstUI (New
England BioLabs) and analysed by agarose gel electro-
phoresis. The G allele (H131) yielded fragments of 120
and 23 bp; the A allele (R131) was not digested (143 bp).
Statistical analyses
In both populations demographic, clinical and biochem-
ical characteristics were compared in a descriptive way.
Differences in genotype distribution among cases were
compared with values predicted by the Hardy-Weinberg
equilibrium. The odds ratio (OR) and 95% confidence
intervals (CI) for the presence of CHD were assessed by
multivariable logistic regression analysis, adjusted for tra-
ditional cardiovascular risk factors, given the HH131 gen-
otype compared to RR131 and/or RH131 genotypes. TheBMC Medical Genetics 2009, 10:46 http://www.biomedcentral.com/1471-2350/10/46
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following established risk factors were used in the fully
adjusted models: in MONICA, age, sex, years of educa-
tion, alcohol consumption, smoking status, BMI, history
of hypertension, history of diabetes, HDLc; in LURIC, age,
sex, smoking status, BMI, history of hypertension, history
of diabetes, and HDLc. Finally, we calculated a power
assessment: A two group Chi-square test based on a two-
sided α of 0.050 and a power of 80%was used to estimate
which statistically significant excess risk (Odds ratio)
between cases and control of each study could be detected
at minimum based on the proportions of the genotype
HH131 versus the other two genotypes combined.
Results
Table 1 shows demographic characteristics of the MON-
ICA case-control study. The study participants were pre-
dominantly men (88.4%). Patients on average had a
lower school education, lower alcohol consumption, were
more often current- or ex-smokers and also more often
had a history of hypertension and DM. BMI and HDLc
were similar in both groups. Patients had a geometric
mean CRP plasma value of 2.06 mg/L and a mean total
cholesterol value of 224 mg/dl. The corresponding levels
in controls were 1.49 mg/L for CRP and 241 mg/dl for
total cholesterol. The lower level of total cholesterol in
patients was due to a more frequent prescription of lipid-
lowering drugs.
Table 2 presents characteristics of participants of the
LURIC study. Patients on average were three years older,
were more often current- or ex- smokers, and more fre-
quently had a history of hypertension and DM. BMI,
HDLc and total cholesterol were similar in both groups.
Lipid-lowering drugs, predominantly statins (>97%),
were used by 61.2% of CHD patients and by 22.2% of
controls. While the average CRP level in patients was 2.86
mg/L (CRP concentration of 1,278 CAD patients with >
50% stenosis with acute coronary syndromes, and unsta-
ble angina pectoris were disregarded) this value was 2.55
mg/L in controls.
Table 3 shows the genotype frequencies of the FcγRIIa
gene among cases and controls. Genotype frequencies in
cases and controls, in both populations, did not show a
significant departure from the Hardy-Weinberg equilib-
rium. Furthermore, neither in the MONICA population,
nor in the LURIC population a difference among cases
and controls with respect to FcγRIIa genotypes existed (p
= 0.86 in MONICA and p = 0.64 in LURIC).
Table 4 presents the partially and fully adjusted ORs
obtained by logistic regression analysis for the presence of
CHD associated with FcγRIIa genotypes. In the MONICA
population, the OR for the presence of CHD associated
with the HH genotype was 0.92 (95% CI, 0.65 to 1.31)
after adjustment for age and gender and increased to 1.01
(95% CI, 0.69 to 1.48) after adjustment for other covari-
ates (Table 4). If the RR and the RH genotype were taken
as reference, the OR associated with the HH genotype was
0.99 (95% CI, 0.75 to 1.28) after adjustment for age and
gender, and increased to 1.08 (95% CI, 0.81 to 1.44) after
additional adjustment for other covariates.
In the LURIC population, the OR for CHD associated with
the HH genotype in the LURIC population was 0.99 (95%
CI, 0.81 to 1.12) after adjustment for age and gender and
1.01 (95% CI, 0.82 to 1.25) after further adjustment for
other traditional cardiovascular risk factors. Again, if the
Table 1: Characteristics of Patients with CHD and Controls: MONICA Study
CHD patients Controls
n 527 527
Age, μ (SD) 56.4 (7.1) 56.3 (7.0)
Males (%) 88.4 88.4
School education 9 years or less (%) 66.2 58.8
Average alcohol consumption per day (g) μ (SD) 17.8 (21.7) 26.5 (28.6)
Teetotalers (%) 29.1 19.9
Smoking status (%):
current smoker 14.6 23.9
ex-smoker 67.6 35.5
never smoker 21.8 40.6
Body mass index (kg/m2), μ (SD) 28.4 (3.7) 28.3 (4.0)
History of high blood pressure (%) 54.8 30.7
History of diabetes mellitus (%) 15.8 7.0
Total cholesterol, mg/dl μ (SD) 224.3 (44.4) 240.6 (47.0)
HDL cholesterol, mg/dl μ (SD) 46.9 (14.3) 48.7 (14.3)
CRP, mg/L * 2.1 1.5
* geometric mean; HDL: high-density lipoprotein. CRP: C-reactive proteinBMC Medical Genetics 2009, 10:46 http://www.biomedcentral.com/1471-2350/10/46
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Table 2: Characteristics of Patients with CHD and Controls: LURIC Study
CHD patients Controls
n 2,227 1,032
Age, μ (SD) 63.8 (10.0) 60.2 (11.4)
Males (%) 77.3 53.9
Smoking status (%):
current smoker 20.6 18.1
ex-smoker 49.8 32.7
never smoker 29.6 49.2
Body mass index (kg/m2), μ (SD) 27.5 (3.9) 27.6 (4.4)
History of high blood pressure (%) 54.3 50.6
History of diabetes mellitus (%) 36.6 21.8
Total cholesterol, mg/dl, μ (SD) 189.5 (39.2) 198.7 (37.4)
HDL cholesterol, mg/dl, μ (SD) 37.2 (10.0) 41.9 (11.7)
CRP, mg/L * 3.9 (1.5–9.3) 2.6 (1.1–6.8)
* median and 25th and 75th percentile, respectively;
HDL: high-density lipoprotein. CRP: C-reactive protein
Table 3: Distribution of FcγRIIa Genotypes and Alleles in CHD Patients and Age- and Gender-Matched Controls in Percent (%): 
MONICA and LURIC Study
MONICA*
Men Women All
Genotype Cases
n = 466
Controls
n = 466
PC a s e s
n = 61
Controls
n = 61
PC a s e s
n = 527
Controls
n = 527
P
RR131 20.6 (n = 96) 19.5 (n = 91) 19.7 (n = 12) 16.4 (n = 10) 20.5 (n = 108) 19.1 (n = 101)
RH131 48.9 (n = 228) 51.5 (n = 240) 59.0 (n = 36) 47.5 (n = 29) 50.1 (n = 264) 51.0 (n = 269)
HH131 30.5 (n = 142) 28.9 (n = 135) 0.73 21.3 (n = 13) 36.1 (n = 22) 0.19 29.4 (n = 155) 29.8 (n = 157) 0.86
Allele
R 45.1 (n = 324) 45.3 (n = 331) 49.2 (n = 48) 40.2 (n = 39) 45.5 (n = 372) 44.7 (n = 370)
H 54.9 (n = 370) 54.7 (n = 375) 50.8 (n = 49) 59.8 (n = 51) 54.5 (n = 419) 55.3 (n = 426)
LURIC*
Men Women All
Genotype Cases
n = 1722
Controls
n = 556
PC a s e s
n = 505
Controls
n = 476
PC a s e s
n = 2227
Controls
n = 1032
P
RR131 21.1 (n = 363) 20.0 (n = 111) 18.4 (n = 93) 19.1 (n = 93) 20.5 (n = 456) 19.6 (n = 202)
RH131 49.1 (n = 846) 47.1 (n = 262) 47.7 (n = 241) 49.4 (n = 235) 48.8 (n = 1087) 48.2 (n = 497)
HH131 29.8 (n = 513) 32.9 (n = 183) 0.38 33.9 (n = 171) 31.5 (n = 150) 0.74 30.7 (n = 684) 32.3 (n = 333) 0.64
Allele
R 45.6 (n = 1209) 43.5 (n = 373) 42.3 (n = 334) 43.8 (n = 328) 44.9 (n = 1543) 43.7 (n = 699)
H 54.4 (n = 1359) 56.5 (n = 445) 57.7 (n = 412) 56.2 (n = 385) 55.1 (n = 1771) 56.3 (n = 830)
*The genotype distribution in LURIC as well as in the MONICA study was in Hardy-Weinberg equilibrium among both patients and controls.BMC Medical Genetics 2009, 10:46 http://www.biomedcentral.com/1471-2350/10/46
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RR and RH genotypes were taken as reference, the OR for
the association of CHD with the HH genotype was 0.96
(95% CI, 0.81 to 1.13) after partial adjustment for age and
gender, and did not change (0.96, 95% CI, 0.81 to 1.14)
after multivariable adjustment.
Discussion
We expected carriers of the HH131 genotype to have a
lower risk of CHD because of the strongly decreased bind-
ing of CRP to cells expressing the specific FcγIIa receptor.
However, results from these two large independent case-
control studies do not suggest that the HH131 genotype
of FcγRIIa may be associated with a lower risk of CHD.
Association between FcγRIIa genotype and CHD
Recently published experimental data are in support of
the negative findings in our populations. It was shown
that CRP binding to monocytes from R131 homozygotes
and RH131 heterozygotes was dose-dependent and satu-
rable at approximately 100 mg/L of CRP. The binding
avidities of CRP for monocytes from R131 homozygous
and RH131 heterozygous donors were 24 and 75 mg/L,
respectively [24]. This value is in the range of CRP concen-
trations present in sera from patients with rather mild to
moderate acute phase responses than concentrations pos-
tulated in CAD [30]. Since average CRP levels in both pop-
ulations were less than 4 mg/L, and monocytes from R131
homozygotes bound CRP with an high apparent affinity
of 24 mg/L, receptor kinetics do not allow a significant
increase in receptor up-regulation. These results are con-
cordant with the observation, that maximum levels of sig-
nalling response of FcγRIIa to CRP in differentiated HL-60
granulocytes was recorded at 100–200 mg/L. Thus, one
can hypothesize that, although having a lower affinity for
the potentially pro-atherogenic CRP, individuals bearing
the H131 allele do not benefit, since the concentration of
CRP is too low to rise the receptor level in atherosclerotic
plaque sufficiently.
As expected, crystal structure analyses showed that the
amino-acid position 131 is critical for the interaction with
the IgG-Fc-tail [31], and the allelic variants of the FcγR
possess distinct phagocytic capacities. The H131 allele is
the only FcγR that recognizes IgG2 efficiently, which is the
main antibody subtype directed against encapsulated bac-
teria [9]. In certain conditions gram-negative bacteria may
get into the circulation on a daily basis, and thereby stim-
ulate IgG2 production, which plays a pivotal role in
phagocytosis of such bacteria [32]. Inflammation, an
essential feature in atherosclerosis may be triggered by
infectious pathogens [33,34]. It was thought that athero-
sclerotic cells expressing the HH131 genotype may be less
capable for atherosclerosis by being more effective in
cleaning IgG2 immune complexes. Several in vitro studies
demonstrated reduced phagocytosis of IgG2-opsonized
particles in cells from individuals homozygous for
FcγRIIa-R131 [35]. However, this needs to be discussed
critically, as the possibility of CRP-mediated phagocytosis
was not taken into consideration sufficiently. CRP binds
to encapsulated bacteria like S. pneumoniae and H. influ-
enza, and maybe in this way provides partial protection
from encapsulated infectious pathogens in individuals
bearing the R131 allele of FcγRIIa, contributing to a reduc-
tion of atherosclerotic risk [24]. The opsonization of S.
Table 4: Partly and Fully Adjusted Odds Ratios for CHD Associated With FcγRIIa Genotypes: MONICA and LURIC Study
Genotype Partly-adjusted OR (95% CI) Multivariable-adjusted OR (95% CI)
MONICA*
RR131 1 reference 1 reference
RH131 0.92 (0.66–1.26) 0.91 (0.65–1.29)
HH131 0.92 (0.65–1.31) 1.01 (0.69–1.48)
RR or RH 131 1 reference 1 reference
HH131 0.99 (0.75–1.28) 1.08 (0.81–1.44)
LURIC**
RR131 1 reference 1 reference
RH131 0.95 (0.76–1.18) 0.97 (0.77–1.21)
HH131 0.99 (0.81–1.12) 1.01 (0.82–1.25)
RR or RH 131 1 reference 1 reference
HH131 0.96 (0.81–1.13) 0.96 (0.81–1.14)
*Partly-adjusted for age and gender; Multivariable-adjusted for age, gender, years of education, alcohol consumption, smoking status, BMI, history of 
hypertension and diabetes, HDL-cholesterol **Partly-adjusted for age and gender; Multivariable-adjusted for age, gender, smoking status, body mass 
index, history of hypertension, history of diabetes, HDL-cholesterolBMC Medical Genetics 2009, 10:46 http://www.biomedcentral.com/1471-2350/10/46
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pneumoniae, in the presence of CRP, primarily activates the
classical complement pathway and complement is
required for the protection by CRP. However, CRP protec-
tion does not require FcγR, indicating that CRP is not pri-
marily protective by direct opsonization but by
complement and the subsequent opsonophagocytosis
[36]. CRP and complement were also shown to be neces-
sary for serum bactericidal activity against H. influenza.
Using a CRP transgenic mouse model, CRP has also been
shown to be protective against gram-negative bacterium
[37-39]. This counterbalance of different CRP binding-
capacities may affect the contribution of FcγRIIa alleles to
host defense and autoimmunity.
In summary, one can hypothesize that there is a critical
counterbalance between complement activation by CRP
and subsequent protection of bacteria-induced inflamma-
tion and cardiovascular disease and the proatherogenic
role of CRP in both, the case of strong binding and the
case of weak binding of CRP.
Recently three studies suggested the possibility that FcγRI
could be the high-affinity receptor for CRP [40-42]. Using
ultrasensitive confocal fluorescence microscopy they
demonstrated that CRP indeed does bind to FcγRIIa,
although with lower affinity than described earlier. Fur-
thermore they studied CRP binding to transfected COS-7
cells expressing the high-affinity IgG receptor FcγRI. They
showed that CRP binds to FcγRI on intact cells, with a kd
of 10 ± 3 μmol/L. Transfection of COS-7 cells with a plas-
mid coding for both FcγRI and its functional counterpart,
the  γ-chain, markedly increased CRP affinity to FcγRI,
resulting in a kd of 0.35 ± 0.10 μmol/L. However, results
of the recently published studies remain controversial,
therefore further research is needed before FcγRI might be
established as a high-affinity receptor for CRP.
Strengths and limitations of our study
Our study has several strengths that need to be men-
tioned. We carefully selected cases and controls and, in
addition, we extensively recorded conventional risk fac-
tors in order to assess their potential for confounding and
carried out adjustments in multivariate models. The large
sample sizes and the independency of the two popula-
tions also contribute to the strength of this study. In the
MONICA population, all analyses were done in patients
with a history of prior MI and compared to population-
based controls. In the LURIC population, consecutive
cases with angiographically proven stenosis of a major
coronary artery of at least 50% were included. Since the
FcγRIIa could not be found in mice, such well designed
epidemiological studies are of considerable interest in
investigating the receptor.
Our study also has some limitations. We used a case-con-
trol design in both populations, therefore the temporal
relationship of the plasma parameters and disease is diffi-
cult to establish. However the temporal relationship of
genotype and CHD is certain. Selection and survival bias
may represent a further problem. The appropriateness of
the control group of the LURIC study deserves discussion.
Early lesions undetectable by angiography could not be
ruled out in controls, nor was coronary microvascular dys-
function. Nevertheless, coronary angiography remains the
gold standard for the diagnosis of clinically relevant CAD,
and it is well known that the future incidence of cardiac
events is low in subjects with normal coronary angi-
ograms. Although the present study did not have the
power to detect a very weak association between FcγRIIa
genotypes (i.e. HH131 vs. others) and CHD, it had a
power of 80% to detect an OR of 1.46 (α = 0.05) or larger
in the MONICA study and an OR of 1.26 or larger in the
LURIC study.
Conclusion
Our results do not suggest an independent and clinically
relevant relationship of the FcγRIIa gene polymorphism
with risk of CAD. Consequently, it seems unlikely that, in
the population studied, FcγRIIa R(-131) → H genotype
represents a promising tool for identifying those at
increased risk for CHD.
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noglobulin; IL: interleukin; KORA: Cooperative Research
in the Region of Augsburg; LDLc: low-density lipoprotein
cholesterol; LURIC: LUdwigshafen RIsk and Cardiovascu-
lar Health; MI: myocardial infarction; MMP: matrix met-
alloproteinase; MONICA: MOnitoring trends and
determinants in CArdiovascular disease; OR: odds ratio;
PAI: plasminogen activator inhibitor; TNF: tumour necro-
sis factor; VCAM: vascular cell adhesion molecule.
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